MedPath

Safety and efficacy of autologous stem cells derived from bone marrow in treating Osteoarthritis

Phase 1
Registration Number
CTRI/2010/091/001044
Lead Sponsor
International Stemcell Services Limited117, Venkateshwara Nagar, Jakkur, Bengaluru 560064
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
10
Inclusion Criteria

1. Must be able to give voluntary written (patients may not be able to write) consent.
2. Must be able to understand study information provided to him.
3. Age 30 to 70, inclusive
OA Kellgren and Lawrence classification 3 & 4
No ligamentous laxity i.e. stable
Ability to understand and willingness to sign consent form
The participant is able to comply with and understand the required visit schedule and all required tests and procedures.

Exclusion Criteria

Serious pre-existing medical conditions like Diabetes Mellitus, Chronic Renal Failure, Rheumatoid Arthritis, Collagen vascular diseases and Autoimmune diseases
Pregnant or lactating woman
Inflammatory arthritis
Oral steriod, methotrexate (immune suppressants)
History of drug or alcohol abuse or chronic smoking
Poor patient compliance
Infectious disease test positive for HIV 1&2, HbsAg, HCV and VDRL.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.To establish safety of stem cell therapy in patients with osteoarthritis <br>2.To assess short and long term efficacy of stem cell therapy in OsteoarthritisTimepoint: 3 months, 6 months, 1 year
Secondary Outcome Measures
NameTimeMethod
Changes in the MRI knee with cartilage mapping and clinical improvement.Timepoint: 3 months, 6 months, 1 year
© Copyright 2025. All Rights Reserved by MedPath